Fusion Pharmaceuticals
9 known investors
Fusion Pharma develops targeted alpha therapeutics for cancer treatment using proprietary linker technology to connect alpha-emitting medical isotopes to cancer-targeting molecules, delivering lethal damage to tumor cells while minimizing toxicity to healthy tissues.
Investors · 9
FACIT (Fight Against Cancer Innovation Trust)Toronto · $1.1M
HealthCapStockholm
Lumira VenturesToronto · $1M – $10M
Seroba Life SciencesDublin · $540K – $7.6M
Venture OntarioToronto
Ysios CapitalBarcelona · $5.4M – $21.6M
Adams Street PartnersreportedChicago · $150M – $750M
Genesys CapitalreportedToronto · $730K – $3.6M
Johnson & Johnson Innovation – JJDCreportedNew Brunswick
In the news
- Fusion Pharma fetches $213m in IPO - Global Venturingglobalventuring.com · 2020
- Hamilton's Fusion Pharmaceuticals Raises $26 Million CAD - Innovation Factoryinnovationfactory.ca · 2020
- Precision oncology startup Fusion Pharmaceuticals raises $26 million CAD | BetaKitbetakit.com · 2020
- Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing - HealthCaphealthcap.eu · 2019
- Fusion Pharmaceuticals Secures Additional $21M; Closes $46M Series A financing - FinSMEsfinsmes.com · 2017
- Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments - Fusion Pharmafusionpharma.com · 2017